The most recently published study evaluating multiple CSF molecules in a group of patients with different clinical forms of MS and other inflammatory and non-inflammatory neurological disorders suggested CSF CXCL13 and CHI3L1 levels as very good prognostic biomarkers in relapsing MS patients, including CIS conversion to definitive MS and clinical and radiological disease activity [56]. This evidence concerns the gene CHI3L1 and in situ carcinoma.